Alzheimer's disease (AD), which is the most common type of dementia, is a neurodegenerative disease that, in its most common form, is found in elderly people. Clinical signs of AD are characterized by progressive cognitive deterioration together with declining activities of daily living and by neuropsychiatric symptoms or behavioral changes. Currently available medications offer relatively small symptomatic benefit for some patients, but do not slow disease progression. One of the consistent findings in the brains of AD patients is a reduction of the functions mediated by the chemical mediator acetylcholine (ACh). The cholinergic approach to treatment of AD involves counteracting this loss in cholinergic activity by pharmacological intervention to increase cholinergic transmission which, to date, represents the only clinical effective approach for treatment of AD. Cholinergic drugs, also known as cholinergic agents, are drugs that enhance the effects mediated by acetylcholine in the central nervous system, the peripheral nervous system, or both. These include acetylcholine's precursors, acetylcholine receptor ligands and cholinergic enzyme inhibitors. The aim of the present project is to develop new molecules able to enhance cholinergic activity through a selective interaction with a specific protein (named Muscarinic M2 receptor) and consequent inhibition of the physiological functions induced by its stimulation.